Pelthos Therapeutics Stock Performance
| PTHS Stock | 26.50 0.48 1.78% |
The company holds a Beta of 1.56, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Pelthos Therapeutics will likely underperform. At this point, Pelthos Therapeutics has a negative expected return of -0.056%. Please make sure to check Pelthos Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Pelthos Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pelthos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable technical indicators, Pelthos Therapeutics is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return (1.78) | Five Day Return 18.2 | Year To Date Return 124.58 | Ten Year Return 124.58 | All Time Return 124.58 |
1 | Pelthos rolls out campaign aimed at moms who dont mess around - Fierce Pharma | 10/10/2025 |
2 | Will Pelthos Therapeutics Inc. stock beat growth indexes - 2025 Bull vs Bear Growth-Oriented Investment Plans - newser.com | 10/17/2025 |
3 | Acquisition by Ligand Pharmaceuticals Inc of tradable shares of Pelthos Therapeutics at 34.442 subject to Rule 16b-3 | 11/06/2025 |
4 | Pelthos Therapeutics Acquires Xepi Cream, 1 percent and Announces 18 Million Private Convertible Notes Financing | 11/07/2025 |
5 | LGND Target Up On Improved Growth Outlook | 11/10/2025 |
6 | Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results | 11/13/2025 |
7 | Disposition of 2000 shares by Friedberg Ezra M of Pelthos Therapeutics at 28.005 subject to Rule 16b-3 | 11/25/2025 |
8 | Unravel Biosciences Announces Approval by Colombian Health Regulatory Authority to Initiate RVL-001 Clinical Studies for Rett Syndrome and Pitt Hopkins Syndrome | 12/02/2025 |
9 | Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI Topical Gel, 10.3 | 12/04/2025 |
10 | Disposition of 9542 shares by Pauls Matthew of Pelthos Therapeutics subject to Rule 16b-3 | 12/10/2025 |
11 | Pelthos Therapeutics Adds Veteran Finance Executive to Board - TipRanks | 12/23/2025 |
| Begin Period Cash Flow | 96.4 K | |
| Free Cash Flow | -5.8 M |
Pelthos Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,000 in Pelthos Therapeutics on September 27, 2025 and sell it today you would lose (350.00) from holding Pelthos Therapeutics or give up 11.67% of portfolio value over 90 days. Pelthos Therapeutics is currently does not generate positive expected returns and assumes 5.3871% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Pelthos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pelthos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pelthos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pelthos Therapeutics, and traders can use it to determine the average amount a Pelthos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0104
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PTHS |
Based on monthly moving average Pelthos Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pelthos Therapeutics by adding Pelthos Therapeutics to a well-diversified portfolio.
Pelthos Therapeutics Fundamentals Growth
Pelthos Stock prices reflect investors' perceptions of the future prospects and financial health of Pelthos Therapeutics, and Pelthos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pelthos Stock performance.
| EBITDA | (7.17 M) | ||||
| Net Income | (7.96 M) | ||||
| Total Debt | 2.19 M | ||||
| Cash Flow From Operations | (5.79 M) | ||||
| Total Asset | 1.37 M | ||||
| Retained Earnings | (21.47 M) | ||||
| Working Capital | (2.71 M) | ||||
About Pelthos Therapeutics Performance
Assessing Pelthos Therapeutics' fundamental ratios provides investors with valuable insights into Pelthos Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Pelthos Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.81) | (6.10) | |
| Return On Capital Employed | 2.79 | 2.93 | |
| Return On Assets | (5.81) | (6.10) | |
| Return On Equity | 2.93 | 3.08 |
Things to note about Pelthos Therapeutics performance evaluation
Checking the ongoing alerts about Pelthos Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pelthos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pelthos Therapeutics generated a negative expected return over the last 90 days | |
| Pelthos Therapeutics has high historical volatility and very poor performance | |
| Pelthos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Pelthos Therapeutics was previously known as CHRO Old and was traded on NASDAQ Exchange under the symbol CHRO. | |
| Net Loss for the year was (7.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Pelthos Therapeutics generates negative cash flow from operations | |
| Pelthos Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Pelthos Therapeutics Adds Veteran Finance Executive to Board - TipRanks |
- Analyzing Pelthos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pelthos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Pelthos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pelthos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pelthos Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pelthos Therapeutics' stock. These opinions can provide insight into Pelthos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pelthos Stock Analysis
When running Pelthos Therapeutics' price analysis, check to measure Pelthos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pelthos Therapeutics is operating at the current time. Most of Pelthos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pelthos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pelthos Therapeutics' price. Additionally, you may evaluate how the addition of Pelthos Therapeutics to your portfolios can decrease your overall portfolio volatility.